Boston Scientific Stock Price, News & Analysis (NYSE:BSX)

$26.70 +0.22 (+0.83 %)
(As of 02/23/2018 10:14 AM ET)
Previous Close$26.48
Today's Range$26.50 - $26.78
52-Week Range$24.02 - $29.93
Volume680,637 shs
Average Volume9.08 million shs
Market Capitalization$36.81 billion
P/E Ratio378.29
Dividend YieldN/A
Beta0.81

About Boston Scientific (NYSE:BSX)

Boston Scientific logoBoston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Receive BSX News and Ratings via Email

Sign-up to receive the latest news and ratings for BSX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNYSE:BSX
CUSIP10113710
Phone508-683-4000

Debt

Debt-to-Equity Ratio0.54%
Current Ratio0.68%
Quick Ratio0.50%

Price-To-Earnings

Trailing P/E Ratio378.285714285714
Forward P/E Ratio19.49
P/E Growth1.94

Sales & Book Value

Annual Sales$9.05 billion
Price / Sales4.06
Cash Flow$1.89 per share
Price / Cash14.13
Book Value$5.10 per share
Price / Book5.24

Profitability

Trailing EPS$0.07
Net Income$105 million
Net Margins1.15%
Return on Equity24.27%
Return on Assets9.48%

Miscellaneous

Employees27,000
Outstanding Shares1,374,910,000

Boston Scientific (NYSE:BSX) Frequently Asked Questions

What is Boston Scientific's stock symbol?

Boston Scientific trades on the New York Stock Exchange (NYSE) under the ticker symbol "BSX."

How were Boston Scientific's earnings last quarter?

Boston Scientific Co. (NYSE:BSX) posted its quarterly earnings results on Thursday, February, 1st. The medical equipment provider reported $0.34 earnings per share for the quarter, hitting the consensus estimate of $0.34. The medical equipment provider had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.39 billion. Boston Scientific had a return on equity of 24.27% and a net margin of 1.15%. The firm's quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.30 EPS. View Boston Scientific's Earnings History.

When will Boston Scientific make its next earnings announcement?

Boston Scientific is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Boston Scientific.

What guidance has Boston Scientific issued on next quarter's earnings?

Boston Scientific issued an update on its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $1.35-1.39 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.38. The company issued revenue guidance of $9.650-$9.800 billion, compared to the consensus revenue estimate of $9.60 billion.Boston Scientific also updated its Q1 guidance to $0.30-0.32 EPS.

Where is Boston Scientific's stock going? Where will Boston Scientific's stock price be in 2018?

18 equities research analysts have issued 1-year price objectives for Boston Scientific's shares. Their forecasts range from $26.48 to $35.00. On average, they expect Boston Scientific's stock price to reach $30.59 in the next year. View Analyst Ratings for Boston Scientific.

What are Wall Street analysts saying about Boston Scientific stock?

Here are some recent quotes from research analysts about Boston Scientific stock:

  • 1. According to Zacks Investment Research, "Despite back-to-back hurricances, Boston Scientific managed to registered solid third-quarter show. An improving foreign exchange scenario has also started to contribute to the company’s overall top line performance. The raised guidance is indicative of this bullish trend to continue through the rest of 2017. The company is leaving no stone unturned to strengthen its core business and invest more in global markets. Among the recent developments, worth mentioning is the acquisition of Apama Medical, in the field of atrial fibrillation. On the flip side, Boston Scientific's unimpressive pacemaker performance within the core CRM continues remains a drag. This apart, based on the recent announcement, we believe further delay in relaunch of the earlier-recalled Lotus range of heart devices is expected to hamper sales in 2018 too. In the past three months, Boston Scientific has been trading below the broader industry." (1/30/2018)
  • 2. Canaccord Genuity analysts commented, "We reiterate our BUY rating and $35 year-end target price on shares of BSX. Our key takeaways from our meeting last week with senior management in San Francisco (as well as incremental tidbits we gleaned over the weekend at the North American Neuromodulation Society (NANS) conference in Vegas) support our general hypothesis on the stock: We expect BSX to deliver top- and bottom-line growth rates above the large-cap medical device peer group average over the 2018-2020 timeframe." (1/17/2018)
  • 3. Jefferies Group LLC analysts commented, "We are re-establishing estimates, a Buy rating and $14.00 PT for Flex Pharma. Flex is developing FLX-787, an innovative anti-cramp drug in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth disease (CMT) and multiple sclerosis (MS). We believe CMT , on which we base our PT , has the highest chance of success. We anticipate Ph2 data in 1Q’18 (MS) and 3Q’18 (ALS, CMT). In 2Q’16, Flex launched HOTSHOT , a consumer beverage for exercise- associated muscle cramps that works via the same mechanisms as FLX-787." (9/7/2017)
  • 4. Needham & Company LLC analysts commented, "BSX beat consensus 1Q17 revenue but missed consensus EPS due to expense associated with the Lotus withdrawal. Management raised its revenue guidance but maintained its EPS guidance for 2017. BSX’s organic revenue growth slowed slightly to 9% in 1Q17 from 10% in 4Q16 despite facing a more difficult comp. MedSurg growth accelerated and offset slower Cardiovascular growth as BSX lapped the US Synergy launch. Margins were below expectations with BSX’s gross margin down 170 bps Y/Y and operating margin down 210 bps Y/Y but this was mostly due to the impact of the Lotus withdrawal." (4/27/2017)

Who are some of Boston Scientific's key competitors?

Who are Boston Scientific's key executives?

Boston Scientific's management team includes the folowing people:

  • Michael F. Mahoney, Chairman of the Board, President, Chief Executive Officer (Age 52)
  • Daniel J. Brennan, Chief Financial Officer, Executive Vice President (Age 51)
  • Supratim Bose, Executive Vice President; President, Asia-Pacific, Middle East and Africa (Age 64)
  • Keith D. Dawkins M.D., Global Chief Medical Officer, Executive Vice President (Age 66)
  • Joseph M. Fitzgerald, Executive Vice President; President - Rhythm Management (Age 53)
  • Edward F. Mackey, Executive Vice President - Operations (Age 54)
  • Ian T. Meredith AM, Executive Vice President, Global Chief Medical Officer (Age 60)
  • Michael P. Phalen, Executive Vice President; President - MedSurg (Age 57)
  • Desiree Ann Ralls-Morrison, Senior Vice President, General Counsel, Corporate Secretary (Age 51)
  • Wendy Carruthers, Senior Vice President - Human Resources (Age 48)

Who owns Boston Scientific stock?

Boston Scientific's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.12%), Bollard Group LLC (2.47%), Bank of New York Mellon Corp (1.21%), Geode Capital Management LLC (0.95%), Standard Life Aberdeen plc (0.92%) and Wells Fargo & Company MN (0.87%). Company insiders that own Boston Scientific stock include Daniel J Brennan, David A Pierce, Jeffrey B Mirviss, John Bradley Sorenson, Joseph Michael Fitzgerald, Karen Prange, Keith D Dawkins, Kevin J Ballinger, Maulik Nanavaty, Michael F Mahoney, Michael P Phalen, Supratim Bose, Timothy A Pratt, Valley Gold Master Fund L Sun and Wendy Carruthers. View Institutional Ownership Trends for Boston Scientific.

Who sold Boston Scientific stock? Who is selling Boston Scientific stock?

Boston Scientific's stock was sold by a variety of institutional investors in the last quarter, including Winslow Capital Management LLC, Jennison Associates LLC, American Century Companies Inc., BlackRock Inc., Bank of New York Mellon Corp, Sei Investments Co., Fred Alger Management Inc. and Amundi Pioneer Asset Management Inc.. Company insiders that have sold Boston Scientific company stock in the last year include Daniel J Brennan, David A Pierce, John Bradley Sorenson, Joseph Michael Fitzgerald, Kevin J Ballinger, Maulik Nanavaty, Michael P Phalen, Supratim Bose, Timothy A Pratt and Wendy Carruthers. View Insider Buying and Selling for Boston Scientific.

Who bought Boston Scientific stock? Who is buying Boston Scientific stock?

Boston Scientific's stock was acquired by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, Two Sigma Advisers LP, Wells Fargo & Company MN, Two Sigma Investments LP, Eaton Vance Management, State of Tennessee Treasury Department, OppenheimerFunds Inc. and Sirios Capital Management L P. View Insider Buying and Selling for Boston Scientific.

How do I buy Boston Scientific stock?

Shares of Boston Scientific can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Boston Scientific's stock price today?

One share of Boston Scientific stock can currently be purchased for approximately $26.70.

How big of a company is Boston Scientific?

Boston Scientific has a market capitalization of $36.81 billion and generates $9.05 billion in revenue each year. The medical equipment provider earns $105 million in net income (profit) each year or $0.07 on an earnings per share basis. Boston Scientific employs 27,000 workers across the globe.

How can I contact Boston Scientific?

Boston Scientific's mailing address is 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-683-4000 or via email at [email protected]


MarketBeat Community Rating for Boston Scientific (BSX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  602 (Vote Outperform)
Underperform Votes:  554 (Vote Underperform)
Total Votes:  1,156
MarketBeat's community ratings are surveys of what our community members think about Boston Scientific and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Boston Scientific (NYSE:BSX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.822.762.76
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
12 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $30.59$30.87$31.11$30.39
Price Target Upside: 15.53% upside13.27% upside11.86% upside14.39% upside

Boston Scientific (NYSE:BSX) Consensus Price Target History

Price Target History for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE:BSX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/23/2018Piper Jaffray CompaniesInitiated CoverageOverweight$31.00 -> $26.48LowView Rating Details
2/2/2018Jefferies GroupReiterated RatingHold -> NeutralLowView Rating Details
1/17/2018Canaccord GenuityReiterated RatingBuyLowView Rating Details
1/16/2018Needham & Company LLCReiterated RatingBuy$32.00LowView Rating Details
1/10/2018BarclaysReiterated RatingBuy$32.00LowView Rating Details
1/5/2018Royal Bank of CanadaUpgradeOutperform -> Top PickMediumView Rating Details
1/3/2018Evercore ISIInitiated CoverageIn -> In-Line$27.00MediumView Rating Details
12/12/2017BMO Capital MarketsReiterated RatingBuy$32.00LowView Rating Details
12/4/2017SunTrust BanksSet Price TargetBuy$33.00LowView Rating Details
11/30/2017CowenSet Price TargetBuy$31.00LowView Rating Details
11/30/2017BTIG ResearchUpgradeNeutral -> Buy$31.00MediumView Rating Details
11/29/2017JPMorgan Chase & Co.Reiterated RatingBuyLowView Rating Details
11/29/2017OppenheimerReiterated RatingHoldHighView Rating Details
9/25/2017Stifel NicolausReiterated RatingBuy$32.00LowView Rating Details
6/16/2017Wells Fargo & CoReiterated RatingOutperform$29.50 -> $31.00LowView Rating Details
5/16/2017Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$28.00LowView Rating Details
4/12/2017GuggenheimReiterated RatingBuyLowView Rating Details
2/23/2017Northland SecuritiesReiterated RatingPositiveN/AView Rating Details
10/6/2016CitigroupBoost Price TargetBuy$28.00 -> $29.00N/AView Rating Details
9/1/2016ArgusUpgradeHold -> Buy$23.82 -> $33.00N/AView Rating Details
7/29/2016Credit Suisse GroupReiterated RatingBuyN/AView Rating Details
7/29/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
7/29/2016WedbushBoost Price TargetNeutral$23.00 -> $25.00N/AView Rating Details
7/28/2016BenchmarkBoost Price TargetBuy$25.00 -> $31.00N/AView Rating Details
3/27/2016Morgan StanleyReiterated RatingOverweight$22.00N/AView Rating Details
3/25/2016Bank of AmericaReiterated RatingBuy$23.00N/AView Rating Details
3/18/2016Longbow ResearchInitiated CoverageBuyN/AView Rating Details
3/17/2016NomuraInitiated CoverageBuy$22.00N/AView Rating Details
3/12/2016Deutsche BankReiterated RatingHoldN/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Boston Scientific (NYSE:BSX) Earnings History and Estimates Chart

Earnings by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$0.32N/AView Earnings Details
2/1/2018Q4 2017$0.34$0.34$2.39 billion$2.41 billionViewListenView Earnings Details
10/26/2017Q3 2017$0.31$0.31$2.21 billion$2.22 billionViewN/AView Earnings Details
7/27/2017Q2 2017$0.31$0.32$2.21 billion$2.26 billionViewN/AView Earnings Details
4/27/2017Q1 2017$0.30$0.29$2.08 billion$2.16 billionViewN/AView Earnings Details
2/2/2017Q416$0.29$0.30$2.16 billion$2.19 billionViewListenView Earnings Details
10/26/2016Q316$0.27$0.27$2.07 billion$2.11 billionViewListenView Earnings Details
7/28/2016Q216$0.27$0.27$2.05 billion$2.13 billionViewListenView Earnings Details
4/27/2016Q116$0.24$0.28$1.91 billion$1.96 billionViewListenView Earnings Details
2/4/2016Q415$0.25$0.26$2.00 billion$1.98 billionViewListenView Earnings Details
10/28/2015Q315$0.23$0.24$1.86 billion$1.89 billionViewListenView Earnings Details
7/23/2015Q215$0.21$0.22$1.83 billion$1.84 billionViewListenView Earnings Details
4/28/2015Q115$0.21$0.21$1.78 billion$1.77 billionViewListenView Earnings Details
2/4/2015Q414$0.21$0.22$1.91 billion$1.89 billionViewListenView Earnings Details
10/22/2014Q314$0.20$0.20$1.82 billion$1.85 billionViewListenView Earnings Details
7/24/2014Q214$0.20$0.21$1.87 billion$1.87 billionViewListenView Earnings Details
4/29/2014Q114$0.18$0.20$1.80 billion$1.77 billionViewListenView Earnings Details
2/4/2014Q4$0.13$0.21$1.83 billion$1.84 billionViewListenView Earnings Details
10/24/2013Q313$0.09$0.17$1.73 billion$1.74 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.10$0.18$1.78 billion$1.81 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.09$0.16$1.79 billion$1.76 billionViewListenView Earnings Details
1/29/2013Q4 2012$0.11$0.18$1.76 billion$1.82 billionViewListenView Earnings Details
10/18/2012$0.11($0.52)ViewN/AView Earnings Details
7/26/2012$0.08$0.17ViewN/AView Earnings Details
4/19/2012$0.13$0.15ViewN/AView Earnings Details
2/2/2012$0.08$0.07ViewN/AView Earnings Details
10/20/2011$0.09$0.15ViewN/AView Earnings Details
7/28/2011$0.08$0.17ViewN/AView Earnings Details
4/20/2011$0.04$0.01ViewN/AView Earnings Details
2/1/2011$0.09$0.15ViewN/AView Earnings Details
10/19/2010Q3 2010$0.06$0.12ViewN/AView Earnings Details
7/20/2010Q2 2010$0.03$0.06ViewN/AView Earnings Details
4/26/2010Q1 2010$0.08$0.09ViewN/AView Earnings Details
2/10/2010Q4 2009$0.13$0.20ViewN/AView Earnings Details
10/19/2009Q3 2009$0.14$0.12ViewN/AView Earnings Details
7/20/2009Q2 2009$0.13$0.20ViewN/AView Earnings Details
4/20/2009Q1 2009$0.12$0.13ViewN/AView Earnings Details
1/28/2009Q4 2008$0.13$0.12ViewN/AView Earnings Details
10/21/2008Q3 2008$0.11$0.16ViewN/AView Earnings Details
7/21/2008Q2 2008$0.11$0.13ViewN/AView Earnings Details
4/21/2008Q1 2008$0.12$0.17ViewN/AView Earnings Details
2/4/2008Q4 2007$0.10$0.24ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Boston Scientific (NYSE:BSX) Earnings Estimates

2018 EPS Consensus Estimate: $1.39
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$0.31$0.33$0.32
Q2 20184$0.35$0.36$0.35
Q3 20185$0.33$0.36$0.34
Q4 20184$0.37$0.40$0.38
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Boston Scientific (NYSE:BSX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Boston Scientific (NYSE BSX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.74%
Institutional Ownership Percentage: 87.77%
Insider Trades by Quarter for Boston Scientific (NYSE:BSX)
Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Boston Scientific (NYSE BSX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/9/2018Maulik NanavatySVPSell15,568$25.38$395,115.84View SEC Filing  
2/7/2018Joseph Michael FitzgeraldEVPSell85,227$26.48$2,256,810.96View SEC Filing  
2/1/2018David A PierceSVPSell5,152$27.43$141,319.3629,353View SEC Filing  
1/11/2018David A PierceSVPSell8,763$27.74$243,085.6224,201View SEC Filing  
1/9/2018David A PierceSVPSell5,152$27.00$139,104.0038,116View SEC Filing  
12/29/2017Michael P PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
12/29/2017Michael P. PhalenEVPSell15,835$25.25$399,833.75View SEC Filing  
12/1/2017Timothy A PrattEVPSell10,000$26.04$260,400.00154,681View SEC Filing  
12/1/2017Valley Gold Master Fund L SunInsiderBuy27,431$0.44$12,069.64
11/29/2017Michael P. PhalenEVPSell15,500$26.66$413,230.00View SEC Filing  
11/28/2017Valley Gold Master Fund L SunInsiderBuy408,006$0.45$183,602.70
11/1/2017Timothy A PrattEVPSell10,000$28.22$282,200.00164,681View SEC Filing  
10/30/2017Michael P. PhalenEVPSell15,500$28.42$440,510.00View SEC Filing  
10/4/2017Supratim BoseEVPSell347,137$29.12$10,108,629.44View SEC Filing  
10/2/2017Timothy A PrattEVPSell11,061$29.24$323,423.64174,681View SEC Filing  
9/29/2017Michael P. PhalenEVPSell15,500$28.72$445,160.00View SEC Filing  
9/1/2017Timothy A PrattEVPSell10,104$27.46$277,455.84185,742View SEC Filing  
8/31/2017Maulik NanavatySVPSell57,031$27.28$1,555,805.68View SEC Filing  
8/30/2017Maulik NanavatySVPSell27,031$27.08$731,999.48View SEC Filing  
8/29/2017Michael P. PhalenEVPSell15,500$26.87$416,485.00View SEC Filing  
8/3/2017Wendy CarruthersSVPSell12,433$26.75$332,582.75View SEC Filing  
8/2/2017John Bradley SorensonSVPSell7,900$26.37$208,323.0021,680View SEC Filing  
8/1/2017Timothy A PrattEVPSell10,000$26.67$266,700.00195,846View SEC Filing  
7/31/2017John Bradley SorensonSVPSell2,100$27.15$57,015.0018,880View SEC Filing  
7/31/2017Michael P. PhalenEVPSell15,500$27.13$420,515.00View SEC Filing  
7/11/2017Daniel J BrennanCFOSell92,158$27.48$2,532,501.84235,421View SEC Filing  
7/3/2017Timothy A PrattEVPSell10,000$27.87$278,700.00205,846View SEC Filing  
6/29/2017Michael P. PhalenEVPSell15,500$28.02$434,310.00View SEC Filing  
6/9/2017David A PierceSVPSell13,562$28.00$379,736.0033,701View SEC Filing  
6/2/2017David A PierceSVPSell2,972$27.70$82,324.4028,572View SEC Filing  
6/1/2017Timothy A PrattEVPSell10,000$27.13$271,300.00215,846View SEC Filing  
5/30/2017Michael P. PhalenEVPSell15,500$27.25$422,375.00View SEC Filing  
5/17/2017Kevin J. BallingerEVPSell28,864$26.14$754,504.96View SEC Filing  
5/1/2017Timothy A PrattEVPSell10,000$26.37$263,700.00225,846View SEC Filing  
4/26/2017David A PierceSVPSell10,250$26.00$266,500.0035,850View SEC Filing  
4/26/2017Michael P. PhalenEVPSell34,773$26.00$904,098.00View SEC Filing  
4/10/2017John Bradley SorensonSVPSell2,950$24.66$72,747.0020,980View SEC Filing  
4/3/2017Timothy A PrattEVPSell10,000$24.87$248,700.00235,846View SEC Filing  
3/29/2017Michael P. PhalenEVPSell79,045$24.55$1,940,554.75View SEC Filing  
3/3/2017David A PierceSVPSell25,012$25.01$625,550.1225,600View SEC Filing  
3/3/2017Timothy A PrattEVPSell23,540$25.01$588,735.40245,846View SEC Filing  
2/27/2017David A PierceSVPSell3,417$24.84$84,878.2834,267View SEC Filing  
2/27/2017Timothy A PrattEVPSell4,832$24.84$120,026.88248,758View SEC Filing  
2/7/2017Keith D DawkinsEVPSell80,783$25.21$2,036,539.4375,864View SEC Filing  
1/9/2017David A PierceSVPSell10,232$22.24$227,559.6825,600View SEC Filing  
1/9/2017Timothy A PrattEVPSell6,195$22.24$137,776.80231,273View SEC Filing  
12/1/2016Timothy A PrattEVPSell26,726$20.48$547,348.48260,430View SEC Filing  
8/11/2016John Bradley SorensonSVPSell2,500$23.90$59,750.0012,615View SEC Filing  
8/1/2016Michael F MahoneyCEOSell44,400$24.44$1,085,136.001,388,177View SEC Filing  
8/1/2016Timothy A PrattEVPSell24,000$24.46$587,040.00287,495View SEC Filing  
7/20/2016David A PierceSVPSell2,480$24.03$59,594.4028,080View SEC Filing  
7/20/2016Michael P. PhalenEVPSell35,000$24.03$841,050.00View SEC Filing  
6/1/2016Michael F MahoneyCEOSell100,000$22.69$2,269,000.001,532,577View SEC Filing  
6/1/2016Timothy A PrattEVPSell24,229$22.66$549,029.14301,724View SEC Filing  
5/11/2016John Bradley SorensonSVPSell2,800$22.15$62,020.0015,115View SEC Filing  
5/10/2016Keith D DawkinsEVPSell80,000$22.15$1,772,000.00150,227View SEC Filing  
5/6/2016Jeffrey B MirvissSVPSell24,659$21.94$541,018.4671,975View SEC Filing  
5/3/2016Joseph Michael FitzgeraldEVPSell79,960$21.81$1,743,927.6092,020View SEC Filing  
5/2/2016Michael F MahoneyCEOSell100,000$22.12$2,212,000.001,632,577View SEC Filing  
5/2/2016Timothy A PrattEVPSell24,000$21.93$526,320.00308,724View SEC Filing  
4/27/2016Kevin J BallingerSVPSell111,807$21.62$2,417,267.3483,600View SEC Filing  
4/27/2016Timothy A PrattEVPSell39,927$21.40$854,437.80291,724View SEC Filing  
4/4/2016Jeffrey B MirvissSVPSell18,422$19.00$350,018.0096,634View SEC Filing  
4/1/2016Michael F MahoneyCEOSell100,000$18.90$1,890,000.001,732,577View SEC Filing  
4/1/2016Timothy A PrattEVPSell24,000$18.73$449,520.00355,651View SEC Filing  
3/11/2016Kevin J BallingerSVPSell16,705$18.00$300,690.0046,970View SEC Filing  
3/8/2016Karen PrangeSVPSell14,747$17.27$254,680.6938,395View SEC Filing  
3/2/2016Michael P. PhalenEVPSell10,665$17.17$183,118.0589,309View SEC Filing  
3/1/2016Michael F MahoneyCEOSell100,000$16.96$1,696,000.001,832,577View SEC Filing  
3/1/2016Timothy A PrattEVPSell15,068$16.97$255,703.96338,651View SEC Filing  
2/29/2016Kevin J. BallingerSVPSell2,114$17.17$36,297.38View SEC Filing  
2/29/2016Michael P. PhalenEVPSell1,819$17.19$31,268.61View SEC Filing  
2/25/2016Daniel J BrennanCFOSell103,211$17.22$1,777,293.42202,659View SEC Filing  
2/25/2016Kevin J. BallingerSVPSell1,903$17.48$33,264.44View SEC Filing  
2/25/2016Michael P. PhalenEVPSell34,106$17.28$589,351.68View SEC Filing  
2/17/2016Kevin J. BallingerSVPSell7,616$17.37$132,289.92View SEC Filing  
2/12/2016Charles J DockendorffDirectorBuy30,000$16.49$494,700.0041,598View SEC Filing  
2/8/2016Karen PrangeSVPSell6,216$16.05$99,766.8023,647View SEC Filing  
1/8/2016Timothy A PrattEVPSell7,160$17.67$126,517.20303,776View SEC Filing  
1/7/2016Kevin J BallingerSVPSell19,059$17.73$337,916.0730,323View SEC Filing  
1/5/2016Jeffrey B MirvissSVPSell9,953$18.00$179,154.0082,535View SEC Filing  
12/1/2015Timothy A. PrattEVPSell24,000$18.43$442,320.00282,295View SEC Filing  
11/16/2015Ernest MarioDirectorSell125,000$17.63$2,203,750.0086,032View SEC Filing  
11/9/2015John Bradley SorensonSVPSell4,469$18.68$83,480.925,605View SEC Filing  
11/9/2015Joseph Michael FitzgeraldEVPSell26,220$18.58$487,167.60103,925View SEC Filing  
11/5/2015Timothy A PrattEVPSell19,598$19.00$372,362.00289,295View SEC Filing  
10/28/2015Jeffrey B MirvissSVPSell9,492$18.00$170,856.0081,262View SEC Filing  
10/28/2015Timothy A PrattEVPSell3,500$18.00$63,000.00315,893View SEC Filing  
10/5/2015Timothy A PrattEVPSell3,500$17.34$60,690.00319,393View SEC Filing  
10/1/2015Timothy A. PrattEVPSell17,000$16.33$277,610.00322,893View SEC Filing  
8/21/2015John E AbeleDirectorBuy200,000$16.77$3,354,000.0092,983View SEC Filing  
8/19/2015John E AbeleDirectorBuy200,000$17.48$3,496,000.0092,983View SEC Filing  
8/17/2015John E AbeleDirectorBuy100,000$17.50$1,750,000.00View SEC Filing  
7/7/2015Karen PrangeSVPSell17,456$17.66$308,272.96View SEC Filing  
5/29/2015Maulik NanavatySVPSell71,558$18.52$1,325,254.16View SEC Filing  
5/28/2015Wendy CarruthersSVPSell42,281$17.91$757,252.71View SEC Filing  
5/18/2015Ernest MarioDirectorSell50,000$18.09$904,500.00View SEC Filing  
5/14/2015John E SununuDirectorSell10,000$17.87$178,700.00View SEC Filing  
5/11/2015John Bradley SorensonSVPSell8,735$17.49$152,775.15View SEC Filing  
3/20/2015David A PierceSVPSell18,050$18.00$324,900.00View SEC Filing  
3/20/2015Michael P PhalenEVPSell46,085$17.94$826,764.90View SEC Filing  
3/16/2015Michael P PhalenEVPSell30,022$17.18$515,777.96View SEC Filing  
3/13/2015John Bradley SorensonSVPSell3,830$16.84$64,497.20View SEC Filing  
3/9/2015David A PierceSVPSell2,561$16.54$42,358.94View SEC Filing  
3/3/2015David A PierceSVPSell8,983$16.79$150,824.57View SEC Filing  
3/3/2015Michael P PhalenEVPSell12,768$16.79$214,374.72View SEC Filing  
2/27/2015David A PierceSVPSell19,046$16.80$319,972.80View SEC Filing  
2/27/2015Michael P PhalenEVPSell1,819$16.80$30,559.20View SEC Filing  
2/19/2015David A PierceSVPSell11,958$16.46$196,828.68View SEC Filing  
2/19/2015Michael P PhalenEVPSell13,188$16.44$216,810.72View SEC Filing  
2/10/2015Joseph Michael FitzgeraldEVPSell61,208$14.66$897,309.28View SEC Filing  
2/9/2015David A PierceSVPSell5,000$14.66$73,300.00View SEC Filing  
2/6/2015Kevin J BallingerSVPSell21,408$15.06$322,404.48View SEC Filing  
1/20/2015Michael P PhalenEVPSell10,000$14.54$145,400.00View SEC Filing  
1/8/2015David A PierceSVPSell18,612$14.31$266,337.72View SEC Filing  
1/8/2015Michael P PhalenEVPSell27,589$14.31$394,798.59View SEC Filing  
1/5/2015Michael P PhalenEVPSell10,000$13.75$137,500.00View SEC Filing  
12/10/2014Karen PrangeSVPSell19,753$12.64$249,677.92View SEC Filing  
12/8/2014David A PierceSVPSell5,000$12.90$64,500.00View SEC Filing  
12/1/2014Ernest MarioDirectorSell10,000$12.96$129,600.00View SEC Filing  
11/28/2014Michael F MahoneyCEOBuy11,700$12.89$150,813.00View SEC Filing  
11/10/2014Edward J LudwigDirectorBuy10,000$13.38$133,800.00View SEC Filing  
11/5/2014John E SununuDirectorSell8,997$13.38$120,379.86View SEC Filing  
11/3/2014Ernest MarioDirectorSell10,000$13.30$133,000.00View SEC Filing  
10/8/2014Ernest MarioDirectorSell10,000$12.06$120,600.00View SEC Filing  
9/2/2014Ernest MarioDirectorSell10,000$12.60$126,000.00View SEC Filing  
8/15/2014Michael P PhalenEVPSell11,471$12.58$144,305.18View SEC Filing  
8/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00View SEC Filing  
7/30/2014David A PierceSVPSell157$12.97$2,036.29View SEC Filing  
7/15/2014Michael P PhalenEVPSell67,500$13.04$880,200.00View SEC Filing  
7/1/2014Ernest MarioDirectorSell10,000$12.95$129,500.00View SEC Filing  
6/16/2014Michael P PhalenEVPSell13,500$13.02$175,770.00View SEC Filing  
6/2/2014Ernest MarioDirectorSell10,000$12.88$128,800.00View SEC Filing  
5/15/2014Michael PhalenEVPSell13,500$12.76$172,260.00127,486View SEC Filing  
5/1/2014Ernest MarioDirectorSell10,000$12.58$125,800.00317,855View SEC Filing  
4/15/2014Michael PhalenEVPSell13,500$13.25$178,875.00127,486View SEC Filing  
4/1/2014Ernest MarioDirectorSell10,000$13.55$135,500.00327,855View SEC Filing  
3/17/2014Michael PhalenEVPSell13,500$13.05$176,175.00127,486View SEC Filing  
3/6/2014David PierceSVPSell5,316$13.44$71,447.0443,161View SEC Filing  
3/6/2014Michael PhalenEVPSell7,281$13.44$97,856.64127,486View SEC Filing  
2/27/2014David PierceSVPSell2,057$13.29$27,337.5347,990View SEC Filing  
2/27/2014Michael PhalenEVPSell3,166$13.29$42,076.14130,848View SEC Filing  
2/21/2014David PierceSVPSell3,199$13.22$42,290.7825,600View SEC Filing  
2/21/2014Michael PhalenEVPSell3,222$13.22$42,594.8484,300View SEC Filing  
2/18/2014Michael PhalenEVPSell13,500$13.30$179,550.0087,522View SEC Filing  
2/13/2014Kristina JohnsonDirectorSell18,000$13.01$234,180.003,124View SEC Filing  
2/6/2014Ernest MarioDirectorSell17,104$12.80$218,931.20347,855View SEC Filing  
2/3/2014Ernest MarioDirectorSell10,000$13.19$131,900.00364,959View SEC Filing  
1/6/2014Ernest MarioDirectorSell10,000$12.50$125,000.00374,959View SEC Filing  
12/26/2013Ernest MarioDirectorSell10,000$12.06$120,600.00384,959View SEC Filing  
11/26/2013Jeffrey CapelloCFOSell85,106$11.82$1,005,952.92109,042View SEC Filing  
11/11/2013Jeffrey MirvissSVPSell26,000$11.91$309,660.0039,190View SEC Filing  
8/29/2013Jeffrey CapelloCFOSell525,000$10.68$5,607,000.00147,447View SEC Filing  
8/16/2013Joseph Michael FitzgeraldSVPSell9,202$11.02$101,406.0493,191View SEC Filing  
8/14/2013Kevin BallingerSVPSell38,171$11.28$430,568.8873,519View SEC Filing  
5/31/2013Jeffrey B MirvissSVPSell10,941$9.37$102,517.17View SEC Filing  
5/30/2013Wendy CarruthersSVPSell25,001$9.16$229,009.16View SEC Filing  
5/29/2013Nelda J ConnorsDirectorSell24,116$9.17$221,143.72View SEC Filing  
5/6/2013Ernest MarioDirectorBuy30,000$7.76$232,800.00View SEC Filing  
11/13/2012Nj Nicholas JrDirectorBuy20,000$5.28$105,600.00View SEC Filing  
11/9/2012Nj Nicholas JrDirectorBuy25,000$5.17$129,250.00View SEC Filing  
8/6/2012Ernest MarioDirectorBuy32,000$5.29$169,280.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Boston Scientific (NYSE BSX) News Headlines

Source:
DateHeadline
Piper Jaffray Companies Begins Coverage on Boston Scientific (BSX)Piper Jaffray Companies Begins Coverage on Boston Scientific (BSX)
www.americanbankingnews.com - February 23 at 9:12 AM
Boston Scientific Corporation -- Moodys assigns Baa2 to Boston Scientifics notes; stable outlookBoston Scientific Corporation -- Moody's assigns Baa2 to Boston Scientific's notes; stable outlook
finance.yahoo.com - February 22 at 10:37 AM
Analysts’ Latest Recommendations on Boston Scientific StockAnalysts’ Latest Recommendations on Boston Scientific Stock
finance.yahoo.com - February 21 at 10:41 AM
Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Boston Scientific, Hologic, ResMed, and ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Medical Equipment Stocks -- Boston Scientific, Hologic, ResMed, and ... - PR Newswire (press release)
www.prnewswire.com - February 20 at 3:34 PM
Boston Scientific Corp (BSX) Files 10-K for the Fiscal Year Ended on December 31, 2017Boston Scientific Corp (BSX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 20 at 10:04 AM
US Tax Reform Impacted Boston Scientific’s Profits in 4Q17US Tax Reform Impacted Boston Scientific’s Profits in 4Q17
finance.yahoo.com - February 20 at 10:04 AM
BSX Interventional Cardiology’s Growth Drivers, Product PipelineBSX Interventional Cardiology’s Growth Drivers, Product Pipeline
finance.yahoo.com - February 19 at 3:34 PM
Drug-Eluting Technologies Drive BSX’s Peripheral InterventionsDrug-Eluting Technologies Drive BSX’s Peripheral Interventions
finance.yahoo.com - February 19 at 9:33 AM
BSX Stock Regains Momentum after Its Recent Bearish TrendBSX Stock Regains Momentum after Its Recent Bearish Trend
finance.yahoo.com - February 16 at 3:37 PM
BSX’s Anticipated Lotus Valve Relaunch: Not before 2019BSX’s Anticipated Lotus Valve Relaunch: Not before 2019
finance.yahoo.com - February 16 at 3:37 PM
Boston Scientific’s 4Q17 Sales Exceeded Analysts’ EstimatesBoston Scientific’s 4Q17 Sales Exceeded Analysts’ Estimates
finance.yahoo.com - February 16 at 3:37 PM
Tiger Managements Top 3 Sells Outweigh Top 3 Buys in 4th QuarterTiger Management's Top 3 Sells Outweigh Top 3 Buys in 4th Quarter
finance.yahoo.com - February 15 at 5:34 AM
Boston Scientific Corporation (BSX) Given Consensus Recommendation of "Buy" by BrokeragesBoston Scientific Corporation (BSX) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 11:48 AM
Boston Scientific Corporation (BSX) SVP Maulik Nanavaty Sells 15,568 SharesBoston Scientific Corporation (BSX) SVP Maulik Nanavaty Sells 15,568 Shares
www.americanbankingnews.com - February 12 at 6:30 PM
How Did BDX’s LifeSciences Business Perform in Fiscal 1Q18?How Did BDX’s LifeSciences Business Perform in Fiscal 1Q18?
finance.yahoo.com - February 12 at 3:16 PM
$2.34 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter$2.34 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter
www.americanbankingnews.com - February 12 at 1:50 AM
Boston Scientific Corporation (BSX) Expected to Post Earnings of $0.31 Per ShareBoston Scientific Corporation (BSX) Expected to Post Earnings of $0.31 Per Share
www.americanbankingnews.com - February 10 at 11:08 PM
Becton Dickinson’s Fiscal 1Q18 Sales Growth of 5.7% Beat EstimatesBecton Dickinson’s Fiscal 1Q18 Sales Growth of 5.7% Beat Estimates
finance.yahoo.com - February 10 at 5:36 AM
Reviewing Invivo Therapeutics (NVIV) and Boston Scientific (BSX)Reviewing Invivo Therapeutics (NVIV) and Boston Scientific (BSX)
www.americanbankingnews.com - February 8 at 7:02 PM
Insider Selling: Boston Scientific Corporation (BSX) EVP Sells 85,227 Shares of StockInsider Selling: Boston Scientific Corporation (BSX) EVP Sells 85,227 Shares of Stock
www.americanbankingnews.com - February 8 at 6:16 PM
Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails - NasdaqMillipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails - Nasdaq
www.nasdaq.com - February 8 at 5:15 AM
Millipede to Aid Boston Scientific, LOTUS Relaunch Lag AilsMillipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails
finance.yahoo.com - February 7 at 5:35 AM
Q2 2018 EPS Estimates for Boston Scientific Corporation (BSX) Reduced by AnalystQ2 2018 EPS Estimates for Boston Scientific Corporation (BSX) Reduced by Analyst
www.americanbankingnews.com - February 5 at 3:50 AM
Analysts Set Expectations for Boston Scientific Corporations Q1 2018 Earnings (BSX)Analysts Set Expectations for Boston Scientific Corporation's Q1 2018 Earnings (BSX)
www.americanbankingnews.com - February 5 at 2:44 AM
Jefferies Group Brokers Raise Earnings Estimates for Boston Scientific Corporation (BSX)Jefferies Group Brokers Raise Earnings Estimates for Boston Scientific Corporation (BSX)
www.americanbankingnews.com - February 5 at 2:44 AM
Boston Scientific (BSX) Q4 Earnings In Line, Revenues Top - NasdaqBoston Scientific (BSX) Q4 Earnings In Line, Revenues Top - Nasdaq
www.nasdaq.com - February 2 at 3:17 PM
Jefferies Group Reaffirms Neutral Rating for Boston Scientific (BSX)Jefferies Group Reaffirms Neutral Rating for Boston Scientific (BSX)
www.americanbankingnews.com - February 2 at 2:52 PM
Boston Scientifics sales beats, forecasts 2018 revenue above estimatesBoston Scientific's sales beats, forecasts 2018 revenue above estimates
www.reuters.com - February 2 at 5:28 AM
Boston Scientific's (BSX) Q4 Earnings In Line, Sales TopBoston Scientific's (BSX) Q4 Earnings In Line, Sales Top
finance.yahoo.com - February 2 at 5:28 AM
Boston Scientific reports Q4 profit, revenue matchesBoston Scientific reports Q4 profit, revenue matches
finance.yahoo.com - February 2 at 5:28 AM
Boston Scientific reports 4Q lossBoston Scientific reports 4Q loss
finance.yahoo.com - February 2 at 5:28 AM
Boston Scientific (BSX) Q4 Earnings In Line, Revenues TopBoston Scientific (BSX) Q4 Earnings In Line, Revenues Top
finance.yahoo.com - February 2 at 5:28 AM
Boston Scientific Corporation (BSX) SVP David A. Pierce Sells 5,152 SharesBoston Scientific Corporation (BSX) SVP David A. Pierce Sells 5,152 Shares
www.americanbankingnews.com - February 1 at 6:28 PM
Boston Scientific Corp Reveals Increase In Q4 Bottom Line - NasdaqBoston Scientific Corp Reveals Increase In Q4 Bottom Line - Nasdaq
www.nasdaq.com - February 1 at 3:16 PM
Boston Scientific reports Q4 profit, revenue matches - MarketWatchBoston Scientific reports Q4 profit, revenue matches - MarketWatch
www.marketwatch.com - February 1 at 3:16 PM
UPDATE 1-Boston Scientifics sales beat, forecasts 2018 revenue above estimatesUPDATE 1-Boston Scientific's sales beat, forecasts 2018 revenue above estimates
finance.yahoo.com - February 1 at 3:16 PM
Sirtex Medical: Varian Medical Systems’ Latest AcquisitionSirtex Medical: Varian Medical Systems’ Latest Acquisition
finance.yahoo.com - February 1 at 3:16 PM
Boston Scientific Tops Fourth-Quarter Sales Views, Earnings In LineBoston Scientific Tops Fourth-Quarter Sales Views, Earnings In Line
finance.yahoo.com - February 1 at 3:16 PM
Abbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 ResultsAbbott Laboratories Traded at a 52-Week High after Posting Strong 4Q17 Results
finance.yahoo.com - February 1 at 3:16 PM
Rationale behind Varian Medical’s Acquisition of Sirtex MedicalRationale behind Varian Medical’s Acquisition of Sirtex Medical
finance.yahoo.com - February 1 at 3:16 PM
Boston Scientifics sales beat; 2018 revenue is forecast above estimatesBoston Scientific's sales beat; 2018 revenue is forecast above estimates
www.cnbc.com - February 1 at 11:08 AM
Boston Scientific (BSX) Announces Quarterly  Earnings ResultsBoston Scientific (BSX) Announces Quarterly Earnings Results
www.americanbankingnews.com - February 1 at 10:02 AM
Boston Scientific (BSX) Releases FY18 Earnings GuidanceBoston Scientific (BSX) Releases FY18 Earnings Guidance
www.americanbankingnews.com - February 1 at 9:31 AM
Boston Scientific (BSX) Issues Q1 Earnings GuidanceBoston Scientific (BSX) Issues Q1 Earnings Guidance
www.americanbankingnews.com - February 1 at 9:30 AM
Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & More - NasdaqMedical Device Stocks Earnings Due on Feb 1: BSX, BAX & More - Nasdaq
www.nasdaq.com - January 31 at 3:16 PM
Medical Device Stocks Earnings Due on Feb 1: BSX, BAX & MoreMedical Device Stocks Earnings Due on Feb 1: BSX, BAX & More
finance.yahoo.com - January 31 at 3:16 PM
Boston Scientific (BSX) Raised to "Hold" at Zacks Investment ResearchBoston Scientific (BSX) Raised to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 30 at 12:30 PM
Boston Scientific to Participate in LEERINK Partners 7th Annual Global Healthcare ConferenceBoston Scientific to Participate in LEERINK Partners 7th Annual Global Healthcare Conference
www.prnewswire.com - January 29 at 8:37 AM
$2.39 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter$2.39 Billion in Sales Expected for Boston Scientific Corporation (BSX) This Quarter
www.americanbankingnews.com - January 27 at 11:48 AM
Boston Scientific's (BSX) Millipede Deal Aids MR BusinessBoston Scientific's (BSX) Millipede Deal Aids MR Business
finance.yahoo.com - January 27 at 5:37 AM

SEC Filings

Boston Scientific (NYSE:BSX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Boston Scientific (NYSE:BSX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Boston Scientific (NYSE BSX) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.